Results 21 to 30 of about 7,168 (203)

In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections

open access: yesJournal of Global Antimicrobial Resistance, 2021
: Objectives: This study reports the antimicrobial activities of ceftaroline and comparators against bacterial isolates from patients with skin and skin-structure infections (2015–2018).
Denis Piérard, Gregory G. Stone
doaj   +1 more source

Etest® versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: results from PREMIUM, a European multicentre study [PDF]

open access: yes, 2016
Objectives: To compare the concordance of ceftaroline MIC values 24 by reference broth microdilution (BMD) and Etest (BioMérieux, France) for MSSA and MRSA isolates, respectively, in isolates from PREMIUM (D372SL00001), a European multi-centre study ...
Arena, Fabio   +69 more
core   +2 more sources

Pathogens of skin and skin-structure infections in the UK and their susceptibility to antibiotics, including ceftaroline [PDF]

open access: yes, 2015
Objectives: Bacterial skin and skin-structure infections (SSSIs) are frequent settings for antibiotic use. We surveyed their UK aetiology and pathogen susceptibility, including susceptibility to ceftaroline.
James, Dorothy   +5 more
core   +1 more source

Treatment of gram - positive infections in critically ill patients [PDF]

open access: yes, 2014
Gram-positive bacteria to include methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), and enterococci, to include vancomycin-resistant enterococci (VRE), display a remarkable array of resistance and ...
Cristina Vazquez-Guillamet   +1 more
core   +2 more sources

Susceptibility testing challenges with ceftaroline, MRSA, and a 1-mg/L breakpoint [PDF]

open access: yes, 2015
Objectives A 1 mg/L susceptibility breakpoint for ceftaroline and staphylococci is universally agreed; EUCAST counts MIC >1 mg/L as resistant whereas CLSI and FDA count 2 mg/L as intermediate and >2 mg/L as resistant.
Clinical and Laboratory Standards Institute   +7 more
core   +1 more source

Susceptibility Patterns of Staphylococcus Aureus Biofilms in Diabetic Foot Infections [PDF]

open access: yes, 2016
BACKGROUND: Foot infections are a major cause of morbidity in people with diabetes and the most common cause of diabetes-related hospitalization and lower extremity amputation. Staphylococcus aureus is by far the most frequent species isolated from these
Cavaco-Silva, P   +6 more
core   +1 more source

New antimicrobials [PDF]

open access: yes, 2017
Since 2010 the new antimicrobials introduced have activity against resistant Gram negative bacteria, long half-lives against Gram positive bacteria, better activity against Clostridium difficile, and safer antifungal properties. Limiting factors to using
Roland, Will
core   +1 more source

Fungi - an Amalgam of Toxins and Antibiotics: a Mini- Review [PDF]

open access: yes, 2020
Fungi are eukaryotes with many functions. Earlier, fungi were classified in the plant kingdom but were later classified as a separate kingdom due to their unique cell walls. Fungi are heterotrophs like animals and are more closely related to animals. The
Ahmed, M. (Muddassir)   +3 more
core  

AmpC β-lactamase induction by avibactam and relebactam [PDF]

open access: yes, 2017
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Jamrozy, Dorota   +5 more
core   +1 more source

Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review. [PDF]

open access: yes, 2018
Background Pneumonia is the most common cause of death in children worldwide, accounting for 15% of all deaths of children under 5 years of age. This review summarises the evidence for the empirical antibiotic treatment of community-acquired pneumonia in
Aga Khan University   +16 more
core   +2 more sources

Home - About - Disclaimer - Privacy